Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
تحليل معلومات السوق
مدعوم بالذكاء الاصطناعيTonix Pharmaceuticals has been approved to uplist from the Nasdaq Capital Market to the Nasdaq Global Select Market, indicating increased market credibility and potentially higher investor interest.
Market impact analysis based on bullish sentiment with 90% confidence.
سياق المقال
BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company’s existing tic
التحليل والرؤى المقدمة من AnalystMarkets AI.